Moss, 14 December 2022

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, has appointed Dr Aleksandra Havelka as its new Chief Scientific Officer
(CSO). Dr Havelka comes from the role as VP Science and Clinical Affairs at
Gentian Diagnostics and was previously Biochemist and Unit Manager at Karolinska
University Laboratory with research focusing on biomarkers for inflammation and
infection.

Dr Erling Sundrehagen (71), who co-founded Gentian in 2001 and has held the CSO
role since 2019, is moving into a new role as Consulting Founder and will
initially devote his time to the development of NT-proBNP. In 2022, Gentian
strengthened its R&D team which now consists of Dr Torsten Knüttel (VP R&D), Dr
Tom Nilsen (Head of Product Development) and Dr Ingo Curdt (Head of Innovation
and Research) who joined the company earlier this year.

In connection with the organizational changes, Dr Sundrehagen says: " We now
have a highly qualified technical team with best-in-class development
capabilities and a track record of bringing industry-changing innovations to the
market. I am confident that Gentian will continue to bring innovative
diagnostics products to the market going forward."  
 
"We are delighted that Aleksandra Havelka, a highly qualified member of our team
and a respected scientist, will take on this new role and further enhance her
close collaboration with the R&D team. After decades of bringing diagnostic
innovations to the market, our co-founder Erling Sundrehagen is pleased to move
into a more consultative role and hand over more of the responsibility to the
competent team that he has helped to form and develop. Erling will continue to
contribute with his insights, focusing on NT-proBNP and the early phase of
developing new products. With Aleksandra as CSO and the strengthening of our R&D
team, Gentian is well-positioned to deliver on its growth ambitions," says Hilja
Ibert, CEO of Gentian Diagnostics. 

The announced changes will take effect from 1 January 2023. 

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.

For further information, please contact:
Hilja Ibert, CEO
hilja.ibert@gentian.no
+47 919 05 242 (mobile)
 
Njaal Kind, CFO and COO
njaal.kind@gentian.no
+47 919 06 525 (mobile)